CDC-RFA-IP21-2105.pdf

Centers for Disease Control and Prevention

National Center for Immunization and Respiratory Diseases

Human Papillomavirus (HPV) Roundtable: Supporting a National Network of Partners to

Promote Cancer Prevention through Human Papillomavirus Vaccination

CDC-RFA-IP21-2105

Application Due Date: 03/22/2021

Human Papillomavirus (HPV) Roundtable: Supporting a National Network of Partners to

Promote Cancer Prevention through Human Papillomavirus Vaccination

CDC-RFA-IP21-2105

TABLE OF CONTENTS

Part I. Overview Information A. Federal Agency Name B. Funding Opportunity Title C. Announcement Type D. Agency Funding Opportunity Number E. Assistance Listings (CFDA) Number F. Dates G. Executive Summary

Part II. Full Text A. Funding Opportunity Description B. Award Information C. Eligibility Information D. Application and Submission Information E. Review and Selection Process F. Award Administration Information G. Agency Contacts H. Other Information I. Glossary

Part I. Overview Information Applicants must go to the synopsis page of this announcement at www.grants.gov and click on the "Subscribe" button link to ensure they receive notifications of any changes to CDC-RFA- IP21-2105. Applicants also must provide an e-mail address to www.grants.gov to receive notifications of changes.

A. Federal Agency Name:

Centers for Disease Control and Prevention (CDC) / Agency for Toxic Substances and Disease Registry (ATSDR) B. Notice of Funding Opportunity (NOFO) Title:

Human Papillomavirus (HPV) Roundtable: Supporting a National Network of Partners to Promote Cancer Prevention through Human Papillomavirus Vaccination C. Announcement Type: New - Type 1 This announcement is only for non-research activities supported by CDC. If research is proposed, the application will not be considered. For this purpose, research is defined at https://www.govregs.com/regulations/title42_chapterI_part2_subpartD_section2.52. Guidance on how CDC interprets the definition of research in the context of public health can be found at https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html (See section 45 CFR 46.102(d)).

New-Type 1

D. Agency Notice of Funding Opportunity Number:

CDC-RFA-IP21-2105

E. Assistance Listings (CFDA) Number:

93.268 F. Dates:

1. Due Date for Letter of Intent (LOI): N/A

2. Due Date for Applications: 03/22/2021, 11:59 p.m. U.S. Eastern

Standard Time, at www.grants.gov.

3. Date for Informational Conference Call:

N/A

G. Executive Summary:

1. Summary Paragraph:

CDC announces the availability of funds to advance a national network of cancer-prevention and immunization stakeholders by creating and supporting a planning committee that prioritizes network activities, updates and disseminates educational resources, and expands the diversity of stakeholders represented within the network that positively impact human papillomavirus (HPV) vaccination rates; convene at least one national meeting of network members to provide technical assistance and catalyze their support of efforts to increase HPV vaccine uptake; and create and support task groups, forums or councils to address priority areas identified by the national network, initiate high-priority pilot projects to reduce barriers to HPV vaccine uptake, and share lessons learned.

https://www.grants.gov https://www.grants.gov https://www.govregs.com/regulations/title42_chapterI_part2_subpartD_section2.52 https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html https://www.grants.gov

By working toward these goals, the network can provide channels of education, outreach, and training structured for the public and health care providers. The network, through its engagement and coordination with stakeholders, will be equipped to increase public and provider understanding of the burden of HPV-associated cancers that can be prevented by HPV vaccination and to accelerate the full implementation of HPV vaccination to prevent HPV-associated cancers.

a. Eligible Applicants: Open Competition

b. NOFO Type: Cooperative Agreement

c. Approximate Number of Awards: 1

d. Total Period of Performance Funding: $2,250,000

e. Average One Year Award Amount: $450,000

f. Total Period of Performance Length: 5

g. Estimated Award Date: 09/01/2021

h. Cost Sharing and / or Matching Requirements: N Cost sharing or matching funds are not required for this program. Although no statutory matching requirement for this NOFO exists, leveraging other resources and related ongoing efforts to promote sustainability is strongly encouraged.

Part II. Full Text A. Funding Opportunity Description

Part II. Full Text

1. Background

a. Overview Every year in the U.S., 14 million people, mostly young adults, become infected with human papillomavirus (HPV.). Certain HPV types cause cancer, including cervical, vulvar, vaginal, penile, anal, and oropharyngeal (base of the tongue, tonsils and back of throat) cancers. Each year in the United States, an estimated 35,900 new cancers attributable to HPV occur: 21,100 among females (of which 11,000 are cervical cancer) and 14,800 among males (of which 14,000 are oropharyngeal cancers). Three HPV vaccines are currently licensed in the United States for prevention of specific HPV types and HPV-associated outcomes. CDC recommends that all children beginning at age 11 or 12 years get 2 doses of HPV vaccine to protect against cancer, ideally by their 13th birthday. However, HPV vaccination can be given as early as 9 years. For girls and boys who start the HPV vaccination series on or after their 15th birthday, the recommended immunization schedule is three doses of HPV vaccine. Currently, HPV vaccination levels and trends in uptake are suboptimal. Coverage with >1 dose of HPV vaccine among adolescent girls aged 13-17 years increased from 60.0% in 2014 to 73.2% in 2019, and among adolescent boys increased from 41.7% in 2014 to 69.8% in 2019. However, in 2019, HPV vaccination coverage remains lower than coverage with Tdap (90.2%) and meningococcal vaccines (88.9%) which are also recommended at age 11-12 years, suggesting persistent missed opportunities for HPV vaccination. If HPV vaccine had been administered during health care visits when another vaccine was administered, vaccination coverage for >1 dose could have reached over 90%. The President's Cancer Panel concluded in its 2012-2013 report to the White House, Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer, that underuse of HPV vaccines was a serious but correctable threat to progress against cancer. The 2018 publi cation of the President?s Cancer Panel Annual Report reinforced the existing goals from the original report to increase HPV vaccination in the United States, while making a call to action by cancer and immunization stakeholders: reduce missed opportunities to recommend and administer HPV vaccine, increase parents' and adolescents' education about and acceptance of HPV vaccination, and maximize access to HPV vaccination services. Increasing understanding and acceptance of and reducing missed opportunities for HPV vaccination will require education of providers and the public about the burden of HPV-related cancers and the availability of a safe and effective vaccine. While HPV itself may be widespread, knowledge of the HPV-associated cancer burden and the urgent need for HPV vaccination to prevent these cancers is not well understood by parents, adolescents or providers who typically provide vaccination to adolescent populations. In contrast to many of the childhood vaccine-preventable diseases such as pertussis and varicella which most physicians have first-hand experience with, the situation is different with HPV-related diseases. Physicians providing HPV vaccine, especially pediatricians, do not routinely see the burden of HPV-related diseases that could be prevented by vaccinating against HPV. Cervical cancer and abnormal Pap smears are more likely to occur after a young woman has moved on from a pediatrician's care. The HPV-related disease that could have been prevented with vaccination is usually seen in obstetric/gynecological, urology and oncology practices.

b. Statutory Authorities This program is authorized under section 317(k)(1) of the Public Health Service Act [42 U.S.C.

247b(k)(1)], as amended.

c. Healthy People 2030 This NOFO supports an overarching Healthy People 2030 goal to "Eliminate health disparities, achieve health equity, and attain health literacy to improve the health and well-being of all".

Additionally, measurable outcomes of the program will be in alignment with Healthy People 2030 goals for immunization and infectious disease https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination).

d. Other National Public Health Priorities and Strategies The NOFO aligns with and supports recommendations of the 2012-2013 President?s Cancer Panel report on HPV, and its 2018 report, including: reduce missed clinical opportunities to recommend and administer HPV vaccine; increase parents? and adolescents? acceptance of HPV vaccination, and maximize access to HPV vaccination services; the CDC National Comprehensive Cancer Control Program (NCCCP) goal to promote the primary prevention of cancer; and the August 2018, National Vaccine Advisory Committee?s recommendation to Stren gthening the Effectiveness of National, State, and Local Efforts to Improve HPV Vaccination Coverage in the United States to improve HPV vaccination coverage rates.

https://prescancerpanel.cancer.gov/report/hpvupdate/index.html https://prescancerpanel.cancer.gov/report/hpvupdate/index.html https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination https://prescancerpanel.cancer.gov/report/hpvupdate/index.html https://prescancerpanel.cancer.gov/report/hpvupdate/index.html https://journals.sagepub.com/doi/full/10.1177/0033354918793629 https://journals.sagepub.com/doi/full/10.1177/0033354918793629 https://journals.sagepub.com/doi/full/10.1177/0033354918793629

e. Relevant Work This NOFO builds on CDC's NOFO, CDC-RFA-IP16-1601, that focuses on similar strategies including creating a national network of stakeholders, convening a national meeting and funding and managing numerous pilot projects to promote cancer-prevention through Human Papillomavirus (HPV) vaccination.

2. CDC Project Description

a. Approach

Bold indicates period of performance outcome.

Bold indicates period of performance outcome

Strategies and Activities Short-term Outcomes Intermediate Outcomes Long-Term Outcomes

Advance a national network of cancer-prevention and immunization stakeholders

· Create and support a planning committee to prioritize network activities

· Disseminate updates and resources to network

Convene national meetings of network members

· Catalyze network to support HPV vaccination uptake

· Provide technical assistance to network members

Create and support task groups, forums or councils to address priority areas identified

Expand the number and variety of organized cancer-prevention and immunization stakeholders within the network

National, state, and local members are more informed about evidence-based practices and HPV vaccination resources

Improve communication between stakeholders about HPV vaccination and cancer-prevention

Increase awareness among health care providers, parents and public about the latest HPV vaccine recommendations, resources, and tools

Prioritize strategies to increase HPV vaccination rates by engaging partners at the national, regional, state, and local level

Increase HPV vaccine uptake strategies used by partners

Increase number of health care providers who employ HPV-specific evidence-based strategies

Increase frequency and quality of HPV vaccine recommendations by health care providers to appropriate populations

Increased HPV vaccination rates

Decrease in HPV-associated cancers https://www.grants.gov/web/grants/search-grants.html?keywords=CDC-RFA-IP16-1601 by national network

· Create pilot projects identified as high priorities for reducing barriers to HPV vaccine uptake

· Share promising practices and lessons learned from pilot projects

Increase identification of promising practices for increasing HPV vaccination rates and preventing HPV-associated cancers

i. Purpose This NOFO will advance a national network of cancer-prevention and immunization stakeholders, convene at least one national meeting of cancer-prevention and HPV immunization stakeholders, and fund and manage pilot project/s to address barriers to HPV vaccine uptake.

These strategies will increase public and provider understanding of the burden of HPV-associated cancers and accelerate the full implementation of HPV vaccination recommendation and vaccine delivery to further the prevention of HPV-associated cancers.

ii. Outcomes Desired program outcomes for this NOFO include:

Expand the number and variety of organized cancer-prevention and immunization stakeholders within the network

Better inform national, state, and local members about evidence-based practices and HPV vaccination resources

Improve communication between stakeholders about HPV vaccination and cancer-prevention

Increase awareness among health care providers, parents and public about the latest HPV vaccine recommendations, resources, and tools

Increase identification of promising practices for increasing HPV vaccination rates and preventing HPV-associated cancers

Increase HPV vaccine uptake strategies used by partners Increase number of health care providers who employ HPV-specific evidence-based strategies Increase frequency and quality of HPV vaccine recommendations by health care providers to appropriate populations

iii. Strategies and Activities Strategy 1: Advance a national network of cancer-prevention and immunization stakeholders.

Applicant can employ strategies such as:

Create and support a planning committee to prioritize network activities Disseminate updates and resources to network

Strategy 2: Convene national meetings of network members.

Applicant can employ strategies such as:

Catalyze network to support HPV vaccination uptake Provide technical assistance to network members

Strategy 3: Create and support task groups, forums, or councils to address priority areas identified by national network.

Applicant can employ strategies such as:

Create pilot projects identified as high priorities for reducing barriers to HPV vaccine uptake.

Share promising practices and lessons learned from pilot projects.

1. Collaborations

a. With other CDC programs and CDC-funded organizations:

Applicants must describe intentions to collaborate with CDC to improve technical and program guidance and evaluation; including CDC’s Immunization Services Division and the Cancer Division of Cancer-prevention and Control. Applicant must also collaborate with other CDC funded partners that are working to increase HPV immunization rates. Collaboration with the partners can be demonstrated by inclusion in the roundtable. Applicants must also describe capacity to participate in stakeholder meetings and other collaborative efforts with public health partners to provide expert consultation to CDC and CDC-funded programs (as requested).

b. With organizations not funded by CDC:

Applicants are required to build and/or continue strategic partnerships and collaborations with cancer-prevention and immunization stakeholders that have a role in achieving the NOFO outcomes and proposed activities. Examples of external partners may include national public, private and non-profit organizations. These collaborators will support the National Roundtable's objectives to increase HPV vaccine uptake.

2. Target Populations The following population groups are the focus of this NOFO: multi-sector participants representing national, regional, state, tribal, territorial, jurisdictional and local level cancer-prevention and immunization stakeholders that will engage with and coordinate their HPV-associated cancer-prevention efforts with those of immunization, public health, provider professional organizations and health department stakeholders to advance implementation of HPV vaccination. The applicant must describe the stakeholders they will partner with including the populations served and the health disparities in cancer and immunization rates among the populations served as a rationale for their involvement in the proposed activities.

a. Health Disparities Despite progress in adolescent HPV vaccination coverage, disparities remain; all adolescents are not equally protected against vaccine-preventable diseases. As in previous years, compared with adolescents living in Metropolitan Statistical Area (MSA) principal cities, HPV Up to Date (UTD) status and coverage with 1 dose of HPV vaccine continues to be lower among adolescents in non-MSA areas. However, these geographic disparities were present only for adolescents at or above the poverty level in 2019. This finding is consistent with another study that found socioeconomic status to be a moderating factor in the association between HPV vaccination and MSA. The lack of an MSA disparity among adolescents below the poverty level might reflect the access that low-income adolescents have to the Vaccines for Children (VFC) program; previous studies have reported higher HPV vaccination coverage rates among adolescents living below the poverty level. Reasons for the MSA disparity among higher socioeconomic status adolescents are less clear but might be an indicator of lower vaccine confidence. More work is needed to understand the relationship between socioeconomic status and geographic disparities and the barriers that might be contributing to such differences*. Disparities also exist between gender, race and ethnicity, respectively. Males aged 17 years have lower HPV vaccination coverage (58.6%) compared with females aged 17 years (72.7%). Non-Hispanic white adolescents have lower coverage (54.7%) compared with Hispanic (69.8%) and non-Hispanic black (65.9%) adolescents**.

The applicant must describe the stakeholders they will partner with, including the populations served, and how their proposed activities, processes, and outcomes will address health disparities in adolescent HPV vaccination rates among those populations.

* Elam-Evans LD, Yankey D, Singleton JA, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years, United States, 2019. MMWR Morb Mortal Wkly Rep 2020;69:1109-1116. DOI: http://dx.doi.org/10.15585/mmwr.mm6933a1.

**Approved by the National Vaccine Advisory Committee on June 25, 2018. (2018).

Strengthening the effectiveness of national, state, and local efforts to improve HPV vaccination coverage in the United States: Recommendations from the National Vaccine Advisory Committee. Public Health Reports, 133(5), 543-550. https://doi.org/10.1177/0033354918793629

iv. Funding Strategy N/A

b. Evaluation and Performance Measurement

i. CDC Evaluation and Performance Measurement Strategy The CDC strategy for monitoring and evaluating program and recipient performance will include several activities, spanning both process and outcomes evaluation, and will be consistent with the logic model and approach presented earlier.

Advance a national network of cancer-prevention and immunization stakeholders by creating and supporting a planning committee to prioritize network activities and disseminating updates and resources to the network.

PROPOSED PROCESS MEASURE(s):

Number of cancer-prevention and immunization stakeholders in network

PROPOSED OUTCOME MEASURE(s):

Increase in number and variety of organized cancer-prevention and immunization stakeholders within the network

Convene national meetings of network members by catalyzing the network to support HPV http://dx.doi.org/10.15585/mmwr.mm6933a1 https://doi.org/10.1177/0033354918793629 vaccination uptake and providing technical assistance to network members.

PROPOSED PROCESS MEASURE(s):

Number of network members who attend national meetings

PROPOSED OUTCOME MEASURE(s):

Increase in number of health care providers who employ HPV-specific evidence-based strategies

Description of successful partnership activities between stakeholders

Create and support task groups, forums or councils to address priority areas identified by national network by creating pilot projects identified as high priorities for reducing barriers to HPV vaccine uptake and sharing promising practices and lessons learned from pilot projects.

PROPOSED PROCESS MEASURE(s):

Number of pilot projects created

PROPOSED OUTCOME MEASURE(s):

Increase in identification of promising practices for increasing HPV vaccination rates and preventing HPV-associated cancers

Increase in HPV vaccine uptake strategies by partners

All measures will be finalized post-award.

Since this NOFO does not involve the generation or collection of public health data, a Data Management Plan is not required for this NOFO.

ii. Applicant Evaluation and Performance Measurement Plan Applicants must provide an evaluation and performance measurement plan that demonstrates how the recipient will fulfill the requirements described in the CDC Evaluation and Performance Measurement and Project Description sections of this NOFO. At a minimum, the plan must describe:

How applicant will collect the performance measures, respond to the evaluation questions, and use evaluation findings for continuous program quality improvement.

How key program partners will participate in the evaluation and performance measurement planning processes.

Available data sources, feasibility of collecting appropriate evaluation and performance data, and other relevant data information (e.g., performance measures proposed by the applicant)

Plans for updating the Data Management Plan (DMP) as new pertinent information becomes available, if applicable, throughout the lifecycle of the project. Updates to DMP should be provided in annual reports. The DMP should provide a description of the data that will be produced using these NOFO funds; access to data; data standards ensuring released data have documentation describing methods of collection, what the data represent, and data limitations; and archival and long-term data preservation plans. For more information about CDC’s policy on the DMP, see https://www.cdc.gov/grants/additional-requirements/ar-25.html.

Where the applicant chooses to, or is expected to, take on specific evaluation studies, they should be directed to:

Describe the type of evaluations (i.e., process, outcome, or both).

Describe key evaluation questions to be addressed by these evaluations.

Describe other information (e.g., measures, data sources).

Recipients will be required to submit a more detailed Evaluation and Performance Measurement plan, including a DMP, if applicable, within the first 6 months of award, as described in the Reporting Section of this NOFO.

c. Organizational Capacity of Recipients to Implement the Approach Applicant should demonstrate, via narrative, workplan, or documentation, at least 10 years of relevant experience and capacity (management, administrative and technical) to implement the activities and achieve the project outcomes, experience and capacity to implement the evaluation plan, and a staffing plan and project management structure sufficient to achieve the project outcomes, including clearly defined staff roles. Applicant must be national in scope. Applicant must have a demonstrated track record of effectively working with cancer-prevention and immunization stakeholders, public health partners, or other key influencers of adolescent vaccination nationally with the ability to support evidence-based interventions and efforts at the local or state level. Applicant must have experience providing technical assistance and resources to CDC funded programs. Applicant must also have appropriate staff to manage the national network, plan and convene a meeting of recruited stakeholders, and administer and monitor the awards for the pilot projects identified by network stakeholders.

Applicant should include copies of CVs/Resumes, Organizational Charts, and narrative explanation of how the applicant demonstrates a track record of working with cancer prevention stakeholders as part of documentation, using the file naming conventions "CVs/Resumes", "Organizational Chart", and "Track Record", respectively, and uploading them as a PDF to www .grants.gov.

d. Work Plan Applicants must identify and address the activities under this NOFO in no more than 20 pages.

Specific details on how the proposed strategies will achieve the outcomes should be included.

CDC will provide feedback and technical assistance to recipients to finalize the work plan during post award. Work Plan must include:

For each strategy, a descriptive plan, process and timeline with milestones/measures A description of the staff and administrative roles and functions to support the project https://www.cdc.gov/grants/additional-requirements/ar-25.html https://www.grants.gov/ work plan and the outcomes. Recipients should identify and assign staff, contractors, and/or consultants, sufficient in number and expertise, to carry out the activities of this

NOFO;

A description of administrative and assessment processes to ensure successful implementation, reporting and quality assurance;

A description of organizational capacity to successfully achieve the project outcomes, including demonstrated experience leading collective action.

e. CDC Monitoring and Accountability Approach Monitoring activities include routine and ongoing communication between CDC and recipients, site visits, and recipient reporting (including work plans, performance, and financial reporting).

Consistent with applicable grants regulations and policies, CDC expects the following to be included in post-award monitoring for grants and cooperative agreements:

Tracking recipient progress in achieving the desired outcomes.

Ensuring the adequacy of recipient systems that underlie and generate data reports.

Creating an environment that fosters integrity in program performance and results.

Monitoring may also include the following activities deemed necessary to monitor the award:

Ensuring that work plans are feasible based on the budget and consistent with the intent of the award.

Ensuring that recipients are performing at a sufficient level to achieve outcomes within stated timeframes.

Working with recipients on adjusting the work plan based on achievement of outcomes, evaluation results and changing budgets.

Monitoring performance measures (both programmatic and financial) to assure satisfactory performance levels.

Monitoring and reporting activities that assist grants management staff (e.g., grants management officers and specialists, and project officers) in the identification, notification, and management of high-risk recipients.

f. CDC Program Support to Recipients (THIS SECTION APPLIES ONLY TO

COOPERATIVE AGREEMENTS)

CDC will provide technical assistance in identifying disparities in immunization, setting program priorities, work plan development, and subject matter expertise. CDC will assist in the review of immunization messages and materials both for technical accuracy and for compliance with proven health education and communication strategies. CDC will share information, practices, lessons learned, and evaluation results through meetings, conference calls, and electronic communication. CDC will monitor the recipient's performance of program activities and progress toward program goals.

B. Award Information

1. Funding Instrument Type: Cooperative Agreement CDC's substantial involvement in this program appears in the CDC Program Support to Recipients Section.

2. Award Mechanism: H23

3. Fiscal Year: 2021

4. Approximate Total Fiscal Year Funding: $450,000

5. Approximate Period of Performance Funding: $2,250,000

This amount is subject to the availability of funds.

Estimated Total Funding: $2,250,000

6. Approximate Period of Performance Length: 5 year(s)

7. Expected Number of Awards: 1

8. Approximate Average Award: $450,000 Per Budget Period

9. Award Ceiling: $0 Per Budget Period

This amount is subject to the availability of funds.

10. Award Floor: $0 Per Budget Period

11. Estimated Award Date: 09/01/2021

12. Budget Period Length: 12 month(s)

Throughout the project period, CDC will continue the award based on the availability of funds, the evidence of satisfactory progress by the recipient (as documented in required reports), and the determination that continued funding is in the best interest of the federal government. The total number of years for which federal support has been approved (project period) will be shown in the “Notice of Award.” This information does not constitute a commitment by the federal government to fund the entire period. The total period of performance comprises the initial competitive segment and any subsequent non-competitive continuation award(s).

13. Direct Assistance Direct Assistance (DA) is not available through this NOFO.

C. Eligibility Information

1. Eligible Applicants

Eligibility Category: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Additional Eligibility Category:

2. Additional Information on Eligibility

3. Justification for Less than Maximum Competition

4. Cost Sharing or Matching Cost Sharing / Matching Requirement: No Cost sharing or matching funds are not required for this program. Although no statutory matching requirement for this NOFO exists, leveraging other resources and related ongoing efforts to promote sustainability is strongly encouraged.

5. Maintenance of Effort Maintenance of effort is not required for this program.

D. Application and Submission Information

1. Required Registrations An organization must be registered at the three following locations before it can submit an application for funding at www.grants.gov.

a. Data Universal Numbering System:

All applicant organizations must obtain a Data Universal Numbering System (DUNS) number.

A DUNS number is a unique nine-digit identification number provided by Dun & Bradstreet (D&B). It will be used as the Universal Identifier when applying for federal awards or cooperative agreements.

The applicant organization may request a DUNS number by telephone at 1-866-705-5711 (toll free) or internet at http:// fedgov.dnb. com/ webform/ displayHomePage.do. The DUNS number will be provided at no charge.

If funds are awarded to an applicant organization that includes sub-recipients, those sub-recipients must provide their DUNS numbers before accepting any funds.

b. System for Award Management (SAM):

The SAM is the primary registrant database for the federal government and the repository into which an entity must submit information required to conduct business as a recipient. All applicant organizations must register with SAM, and will be assigned a SAM number. All http://fedgov.dnb.com/webform/displayHomePage.do information relevant to the SAM number must be current at all times during which the applicant has an application under consideration for funding by CDC. If an award is made, the SAM information must be maintained until a final financial report is submitted or the final payment is received, whichever is later. The SAM registration process can require 10 or more business days, and registration must be renewed annually. Additional information about registration procedures may be found at https://www.sam.gov/index.html.

c. Grants.gov:

The first step in submitting an application online is registering your organization at www.grants.gov, the official HHS E-grant Web site. Registration information is located at the "Applicant Registration" option at www.grants.gov.

All applicant organizations must register at www.grants.gov. The one-time registration process usually takes not more than five days to complete. Applicants should start the registration process as early as possible.

Step System Requirements Duration Follow Up 1 Data

Universal Number System

(DUNS)

1. Click on http:// fedgov.dnb.com/ webform

2. Select Begin DUNS search/request process

3. Select your country or territory and follow the instructions to obtain your DUNS 9-digit #

4. Request appropriate staff member(s) to obtain DUNS number, verify & update information under DUNS number

1-2 Business Days

To confirm that you have been issued a new DUNS number check online at (http:// fedgov.dnb.com/ webform) or call 1-866-705-5711

2 System for Award Management

(SAM)

formerly Central Contractor Registration

(CCR)

1. Retrieve organizations DUNS number

2. Go to https://www.sam.gov/index.

html and designate an E-Biz POC (note CCR username will not work in SAM and you will need to have an active SAM account before you can register on grants.gov)

3-5 Business Days but up to 2 weeks and must be renewed once a year

For SAM Customer Service Contact https://fsd.gov/ fsd-gov/ home.do Calls:

866-606-8220

3 Grants.gov 1. Set up an individual account in Grants.gov using organization new DUNS number to become an authorized organization

Same day but can take 8 weeks to be fully registered

Register early!

Log into grants.gov and check AOR status until it https://www.sam.gov/index.html https://grants.gov/ https://www.grants.gov/ http://www.grants.gov https://www.grants.gov/ http://fedgov.dnb.com/webform http://fedgov.dnb.com/webform http://fedgov.dnb.com/webform http://fedgov.dnb.com/webform http://fedgov.dnb.com/webform https://www.sam.gov/index.html%20 https://www.sam.gov/index.html%20 https://fsd.gov/fsd-gov/home.do https://fsd.gov/fsd-gov/home.do https://fsd.gov/fsd-gov/home.do representative (AOR)

2. Once the account is set up the E-BIZ POC will be notified via email

3. Log into grants.gov using the password the E-BIZ POC received and create new password

4. This authorizes the AOR to submit applications on behalf of the organization and approved in the system (note, applicants

MUST

obtain a

DUNS

number and

SAM

account before applying on grants.gov) shows you have been approved

2. Request Application Package Applicants may access the application package at www.grants.gov.

3. Application Package Applicants must download the SF-424, Application for Federal Assistance, package associated with this notice of funding opportunity at www.grants.gov.

4. Submission Dates and Times If the application is not submitted by the deadline published in the NOFO, it will not be processed. Office of Grants Services (OGS) personnel will notify the applicant that their application did not meet the deadline. The applicant must receive pre-approval to submit a paper application (see Other Submission Requirements section for additional details). If the applicant is authorized to submit a paper application, it must be received by the deadline provided by

OGS.

a. Letter of Intent Deadline (must be emailed or postmarked by) Due Date for Letter of Intent: N/A

b. Application Deadline Due Date for Applications: 03/22/2021 , 11:59 p.m. U.S. Eastern Standard Time, at www.grants.gov. If Grants.gov is inoperable and cannot receive applications, and circumstances preclude advance notification of an extension, then applications must be submitted by the first business day on which grants.gov operations resume.

Date for Information Conference Call N/A

5. CDC Assurances and Certifications All applicants are required to sign and submit “Assurances and Certifications” documents https://www.grants.gov indicated at http://wwwn.cdc.gov/ grantassurances/ (S(mj444mxct51lnrv1hljjjmaa)) /Homepage.aspx.

Applicants may follow either of the following processes:

Complete the applicable assurances and certifications with each application submission, name the file “Assurances and Certifications” and upload it as a PDF file with at www.grants.gov

Complete the applicable assurances and certifications and submit them directly to CDC on an annual basis at http://wwwn.cdc.gov/ grantassurances/ (S(mj444mxct51lnrv1hljjjmaa))/ Homepage.aspx

Assurances and certifications submitted directly to CDC will be kept on file for one year and will apply to all applications submitted to CDC by the applicant within one year of the submission date.

Risk Assessment Questionnaire Requirement CDC is required to conduct pre-award risk assessments to determine the risk an applicant poses to meeting federal programmatic and administrative requirements by taking into account issues such as financial instability, insufficient management systems, non-compliance with award conditions, the charging of unallowable costs, and inexperience. The risk assessment will include an evaluation of the applicant’s CDC Risk Questionnaire, located at https://www.cdc.gov/grants/documents/PPMR-G-CDC-Risk-Questionnaire.pdf, as well as a review of the applicant’s history in all available systems; including OMB-designated repositories of government-wide eligibility and financial integrity systems (see 45 CFR 75.205(a)), and other sources of historical information. These systems include, but are not limited to: FAPIIS (https://www.fapiis.gov/), including past performance on federal contracts as per Duncan Hunter National Defense Authorization Act of 2009; Do Not Pay list; and System for Award Management (SAM) exclusions.

CDC requires all applicants to complete the Risk Questionnaire, OMB Control Number 0920- 1132 annually. This questionnaire, which is located at https://www.cdc.gov/grants/documents/PPMR-G-CDC-Risk-Questionnaire.pdf, along with supporting documentation must be submitted with your application by the closing date of the Notice of Funding Opportunity Announcement. If your organization has completed CDC’s Risk Questionnaire within the past 12 months of the closing date of this NOFO, then you must submit a copy of that questionnaire, or submit a letter signed by the authorized organization representative to include the original submission date, organization’s EIN and DUNS.

When uploading supporting documentation for the Risk Questionnaire into this application package, clearly label the documents for easy identification of the type of documentation. For example, a copy of Procurement policy submitted in response to the questionnaire may be labeled using the following format: Risk Questionnaire Supporting Documents _ Procurement Policy.

Duplication of Efforts Applicants are responsible for reporting if this application will result in programmatic, budgetary, or commitment overlap with another application or award (i.e. grant, cooperative http://wwwn.cdc.gov/grantassurances/(S(mj444mxct51lnrv1hljjjmaa))/Homepage.aspx http://wwwn.cdc.gov/grantassurances/(S(mj444mxct51lnrv1hljjjmaa))/Homepage.aspx https://www.grants.gov http://wwwn.cdc.gov/grantassurances/(S(mj444mxct51lnrv1hljjjmaa))/Homepage.aspx http://wwwn.cdc.gov/grantassurances/(S(mj444mxct51lnrv1hljjjmaa))/Homepage.aspx https://www.cdc.gov/grants/documents/PPMR-G-CDC-Risk-Questionnaire.pdf https://www.cdc.gov/grants/documents/PPMR-G-CDC-Risk-Questionnaire.pdf agreement, or contract) submitted to another funding source in the same fiscal year.

Programmatic overlap occurs when (1) substantially the same project is proposed in more than one application or is submitted to two or more funding sources for review and funding consideration or (2) a specific objective and the project design for accomplishing the objective are the same or closely related in two or more applications or awards, regardless of the funding source. Budgetary overlap occurs when duplicate or equivalent budgetary items (e.g., equipment, salaries) are requested in an application but already are provided by another source.

Commitment overlap occurs when an individual’s time commitment exceeds 100 percent, whether or not salary support is requested in the application. Overlap, whether programmatic, budgetary, or commitment of an individual’s effort greater than 100 percent, is not permitted.

Any overlap will be resolved by the CDC with the applicant and the PD/PI prior to award.

Report Submission: The applicant must upload the report in Grants.gov under “Other Attachment Forms.” The document should be labeled: "Report on Programmatic, Budgetary, and Commitment Overlap.”

6. Content and Form of Application Submission Applicants are required to include all of the following documents with their application package at www.grants.gov.

7. Letter of Intent LOI is not requested or required as part of the application for this NOFO.

8. Table of Contents (There is no page limit. The table of contents is not included in the project narrative page limit.): The applicant must provide, as a separate attachment, the “Table of Contents” for the entire submission package.

Provide a detailed table of contents for the entire submission package that includes all of the documents in the application and headings in the "Project Narrative" section. Name the file "Table of Contents" and upload it as a PDF file under "Other Attachment Forms" at www.grants.gov.

9. Project Abstract Summary (Maximum 1 page) A project abstract is included on the mandatory documents list and must be submitted at www.grants.gov. The project abstract must be a self-contained, brief summary of the proposed project including the purpose and outcomes. This summary must not include any proprietary or confidential information. Applicants must enter the summary in the "Project Abstract Summary" text box at www.grants.gov.

10. Project Narrative (Unless specified in the "H. Other Information" section, maximum of 20 pages, single spaced, 12 point font, 1-inch margins, number all pages. This includes the work plan. Content beyond the specified page number will not be reviewed.)

https://www.grants.gov https://www.grants.gov

Applicants must submit a Project Narrative with the application forms. Applicants must name this file “Project Narrative” and upload it at www.grants.gov. The Project Narrative must include all of the following headings (including subheadings): Background, Approach, Applicant Evaluation and Performance Measurement Plan, Organizational Capacity of Applicants to Implement the Approach, and Work Plan. The Project Narrative must be succinct, self-explanatory, and in the order outlined in this section. It must address outcomes and activities to be conducted over the entire period of performance as identified in the CDC Project Description section. Applicants should use the federal plain language guidelines and Clear Communication Index to respond to this Notice of Funding Opportunity. Note that recipients should also use these tools when creating public communication materials supported by this NOFO. Failure to follow the guidance and format may negatively impact scoring of the application.

a. Background Applicants must provide a description of relevant background information that includes the context of the problem (See CDC Background).

b. Approach

i. Purpose Applicants must describe in 2-3 sentences specifically how their application will address the public health problem as described in the CDC Background section.

ii. Outcomes Applicants must clearly identify the outcomes they expect to achieve by the end of the project period, as identified in the logic model in the Approach section of the CDC Project Description.

Outcomes are the results that the program intends to achieve and usually indicate the intended direction of change (e.g., increase, decrease).

iii. Strategies and Activities Applicants must provide a clear and concise description of the strategies and activities they will use to achieve the period of performance outcomes. Applicants must select existing evidence-based strategies that meet their needs, or describe in the Applicant Evaluation and Performance Measurement Plan how these strategies will be evaluated over the course of the project period.

See the Strategies and Activities section of the CDC Project Description.

1. Collaborations Applicants must describe how they will collaborate with programs and organizations either internal or external to CDC. Applicants must address the Collaboration requirements as described in the CDC Project Description.

2. Target Populations and Health Disparities Applicants must describe the specific target population(s) in their jurisdiction and explain how such a target will achieve the goals of the award and/or alleviate health disparities. The applicants must also address how they will include specific populations that can benefit from the program that is described in the Approach section. Applicants must address the Target Populations and Health Disparities requirements as described in the CDC Project Description.

c. Applicant Evaluation and Performance Measurement Plan Applicants must provide an evaluation and performance measurement plan that demonstrates how the recipient will fulfill the requirements described in the CDC Evaluation and Performance Measurement and Project Description sections of this NOFO. At a minimum, the plan must describe:

How applicant will collect the performance measures, respond to the evaluation questions, and use evaluation findings for continuous program quality improvement. The Paperwork Reduction Act of 1995 (PRA): Applicants are advised that any activities involving information collections (e.g., surveys, questionnaires, applications, audits, data requests, reporting, recordkeeping and disclosure requirements) from 10 or more individuals or non-Federal entities, including State and local governmental agencies, and funded or sponsored by the Federal Government are subject to review and approval by the Office of Management and Budget. For further information about CDC’s requirements under PRA see https://www.cdc.gov/od/science/integrity/reducePublicBurden/.

How key program partners will participate in the evaluation and performance measurement planning processes.

Available data sources, feasibility of collecting appropriate evaluation and performance data, data management plan (DMP), and other relevant data information (e.g., performance measures proposed by the applicant).

Where the applicant chooses to, or is expected to, take on specific evaluation studies, they should be directed to:

Describe the type of evaluations (i.e., process, outcome, or both).

Describe key evaluation questions to be addressed by these evaluations.

Describe other information (e.g., measures, data sources).

Recipients will be required to submit a more detailed Evaluation and Performance Measurement plan (including the DMP elements) within the first 6 months of award, as described in the Reporting Section of this NOFO.

d. Organizational Capacity of Applicants to Implement the Approach Applicants must address the organizational capacity requirements as described in the CDC Project Description.

https://www.cdc.gov/od/science/integrity/reducePublicBurden/

11. Work Plan (Included in the Project Narrative’s page limit) Applicants must prepare a work plan consistent with the CDC Project Description Work Plan section. The work plan integrates and delineates more specifically how the recipient plans to carry out achieving the period of performance outcomes, strategies and activities, evaluation and performance measurement.

12. Budget Narrative Applicants must submit an itemized budget narrative. When developing the budget narrative, applicants must consider whether the proposed budget is reasonable and consistent with the purpose, outcomes, and program strategy outlined in the project narrative. The budget must include:

Salaries and wages Fringe benefits Consultant costs Equipment Supplies Travel Other categories Contractual costs Total Direct costs Total Indirect costs

Indirect costs could include the cost of collecting, managing, sharing and preserving data.

Indirect costs on grants awarded to foreign organizations and foreign public entities and performed fully outside of the territorial limits of the U.S. may be paid to support the costs of compliance with federal requirements at a fixed rate of eight percent of MTDC exclusive of tuition and related fees, direct expenditures for equipment, and subawards in excess of $25,000.

Negotiated indirect costs may be paid to the American University, Beirut, and the World Health Organization.

If applicable and consistent with the cited statutory authority for this announcement, applicant entities may use funds for activities as they relate to the intent of this NOFO to meet national standards or seek health department accreditation through the Public Health Accreditation Board (see: http://www.phaboard.org). Applicant entities to whom this provision applies include state, local, territorial governments (including the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau), or their bona fide agents, political subdivisions of states (in consultation with states), federally recognized or state-recognized American Indian or Alaska Native tribal governments, and American Indian or Alaska Native tribally designated organizations. Activities include those that enable a public health organization to deliver public health services such as activities that ensure a capable and qualified workforce, up-to-date information systems, and the capability to assess and respond to public health needs. Use of http://www.phaboard.org these funds must focus on achieving a minimum of one national standard that supports the intent of the NOFO. Proposed activities must be included in the budget narrative and must indicate which standards will be addressed.

Vital records data, including births and deaths, are used to inform public health program and policy decisions. If applicable and consistent with the cited statutory authority for this NOFO, applicant entities are encouraged to collaborate with and support their jurisdiction’s vital records office (VRO) to improve vital records data timeliness, quality and access, and to advance public health goals.